Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Loretta J. Nastoupil"'
Autor:
Loretta J. Nastoupil, Nada Hamad, John Casey, Chan Yoon Cheah, Andrew Grigg, Collin K. Chin, Peter Wood, Kate Manos, Eliza A Hawkes, Maher K. Gandhi, Katharine L Lewis, Shir Jing Ho, Bryan Do, Julie Crawford, Samar Issa
Publikováno v:
British Journal of Haematology. 192:1049-1053
Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encouraging data have emerged from Phase I/II clinical trials treating relapsed/refractory PCNSL/SCNSL with ibrutinib. We anal
Autor:
Ian W. Flinn, M. Lia Palomba, Sattva S. Neelapu, Peter Martin, Jutta K. Neuenburg, Loretta J. Nastoupil, Nathan Fowler, Raul Mena, Ranjana H. Advani, Darrin M. Beaupre, Karl Eckert, Sven de Vos, Mark Knapp, Sumeet Bhatia, Richard E. Davis, Robert T. Chen, Melannie Co, Jerry Ping
Publikováno v:
British Journal of Haematology
Summary This phase 2 study evaluated the activity and safety of ibrutinib, a Bruton’s tyrosine kinase inhibitor, plus rituximab in adults with previously untreated follicular lymphoma. Patients received once‐daily ibrutinib 560 mg continuously pl
Autor:
Joseph D. Khoury, Loretta J. Nastoupil, Satva S. Neelapu, Luis Fayad, Bouthaina S. Dabaja, Felipe Samaniego, T.Y. Andraos, Jillian R. Gunther, Chelsea C. Pinnix, Nathan Fowler, Sweet Ping Ng, Sarah A. Milgrom, Zeina Ayoub
Publikováno v:
Leukemia & Lymphoma. 60:2432-2440
Controversy exists regarding the optimal management of limited stage grade 3 follicular lymphoma (FL3). We assessed the treatment outcomes of 190 consecutive patients with stage I-II FL. Fifty two patients had FL3 disease, in whom the median age was
Autor:
Marshall T. Schreeder, Julie M. Vose, Matthew A. Lunning, Susan O'Brien, Hari P. Miskin, Loretta J. Nastoupil, Michael S. Weiss, Christopher R. Flowers, William G. Wierda, Jan A. Burger, Jonathon B. Cohen, M. Purdom, Nathan Fowler, Tanya Siddiqi, Peter Sportelli
Publikováno v:
The Lancet Haematology. 6:e100-e109
Summary Background Therapeutic approaches for B-cell malignancies continue to evolve, especially with regard to combination approaches. We assessed the safety and efficacy of the triplet ublituximab, umbralisib, and ibrutinib in patients with advance
Autor:
Melody R. Becnel, Andrew M. Evens, Stephen D. Smith, Pooja Mehra, Amrita Desai, Prathima Reddy, Dhruvika Mukhija, Max L. Goldman, Bita Fakhri, James R. Cerhan, Brad S. Kahl, Abhigna Kodali, Jonathon B. Cohen, Brian K. Link, Juan Pablo Alderuccio, Deepa Jagadeesh, Nilanjan Ghosh, Allison M. Winter, Izidore S. Lossos, Thomas M. Habermann, Mohammad Junaid Hussain, Oscar Calzada, Timothy Tiutan, Peter Martin, Loretta J. Nastoupil, Craig A. Portell, Matthew J. Maurer, Brian T. Hill, Paolo Caimi
Publikováno v:
British journal of haematology, vol 184, iss 4
Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) after BR induction has not been formally compared to observation for FL,
Autor:
Yixin Yao, Lucy Navsaria, Preetesh Jain, Guangchun Han, Shuangtao Zhao, R. Steiner, Michael L. Wang, Xingzhi Song, Swaminathan P. Iyer, Luis Fayad, Dapeng Hao, Ranjit Nair, Holly Hill, Changying Jiang, Sattva S. Neelapu, Francisco Vega, L. J. Medeiros, Wendy Chen, Nathan Fowler, Jorge E. Romaguera, Jorge Aranda, C. Cameron Yin, Guofan Xu, Selvi Thirumurthi, Loretta J. Nastoupil, Chi Young Ok, Jason R. Westin, Omar Moghrabi, Felipe Samaniego, Maria Badillo, Christopher R. Flowers, Shaoying Li, Sairah Ahmed, Onyeka Oriabure, Rashmi Kanagal-Shamanna, Krystle Nomie, Guilin Tang, Keyur P. Patel, Linghua Wang, Jianhua Zhang, Shaojun Zhang
Publikováno v:
American journal of hematologyREFERENCES. 95(6)
Venetoclax is effective in relapsed patients with mantle cell lymphoma (MCL). Mechanisms of resistance to venetoclax in MCL are poorly understood. We describe the clinical outcomes and genomic characteristics of 24 multiply relapsed patients (median
Autor:
Brinda Rao Korivi, Loretta J. Nastoupil, Hun Ju Lee, Sattva S. Neelapu, Nicolaus A. Wagner-Bartak, Ranjit Nair, Swaminathan P. Iyer, Penny Fang, Bouthaina S. Dabaja, Jason R. Westin, Gordon Glober, Simrit Parmar, M. Alma Rodriguez, Jillian R. Gunther, Chelsea C. Pinnix, Corey T. Jensen, Sarah A. Milgrom, Christopher R. Flowers, Sairah Ahmed, Raphael E Steiner, Luis Fayad
Publikováno v:
Clin Lymphoma Myeloma Leuk
Purpose/Objective Early stage Hodgkin lymphoma (ESHL) is highly curable, however 10-15% of patients experience relapse. We examined the utilization of follow-up imaging for ESHL patients who achieved a metabolic complete response after upfront therap
Autor:
Sattva S. Neelapu, Ann S. LaCasce, Jason R. Westin, C. David Fuller, Zeinab Abou Yehia, Hubert H. Chuang, L. Jeffrey Medeiros, Philippe Armand, Bouthaina S. Dabaja, Christine F. Wogan, Wei Qiao, Jillian R. Gunther, Yasuhiro Oki, William Martin-Doyle, Michelle A. Fanale, Andrea K. Ng, Grace L. Smith, Loretta J. Nastoupil, Mani Akhtari, Chelsea C. Pinnix, Sarah A. Milgrom, Osama Mawlawi
Publikováno v:
Blood Advances. 2:1334-1343
Dose-adjusted rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH) has produced good outcomes in primary mediastinal B-cell lymphoma (PMBCL), but predictors of resistance to this treatment are unclear. We
Autor:
Jillian R. Gunther, Chelsea C. Pinnix, Yasuhiro Oki, Jason R. Westin, Sarah A. Milgrom, L. Jeffrey Medeiros, Luis Fayad, Ethan B. Ludmir, Loretta J. Nastoupil, Bouthaina S. Dabaja
Publikováno v:
Leukemia & Lymphoma. 59:2896-2903
Treatment strategies and outcomes were assessed in 25 patients with primary breast diffuse large B-cell lymphoma (PB-DLBCL) treated between 1995 and 2016. We specifically investigated the timing of recurrence, and the roles of radiotherapy (RT) and c
Autor:
Jonathon B. Cohen, Daniel M Guidot, Joseph Maly, Jeffrey M. Switchenko, Loretta J. Nastoupil, Jean L. Koff, Christopher R. Flowers, Kristie A. Blum
Publikováno v:
Leukemia & Lymphoma. 59:888-895
Mantle cell lymphoma (MCL) is a heterogeneous disease with high relapse rates. Limited data guide the use of surveillance imaging following treatment. We constructed a retrospective cohort from two academic institutions of patients with MCL who compl